Subgroup analyses from the phase 3 ASCENT study of sacituzumab govitecan in metastatic triple-negative breast cancer
Abstract In this post hoc analysis of the ASCENT study, we compared outcomes with sacituzumab govitecan (SG) vs single-agent chemotherapy in clinically important subgroups of patients with metastatic triple-negative breast cancer (mTNBC). Patients with mTNBC refractory to/relapsing after ≥2 prior ch...
Na minha lista:
| Principais autores: | , , , , , , , , , , |
|---|---|
| Formato: | Artigo |
| Idioma: | Inglês |
| Publicado em: |
Nature Portfolio
2024-04-01
|
| coleção: | npj Breast Cancer |
| Acesso em linha: | https://doi.org/10.1038/s41523-024-00635-5 |
| Tags: |
Sem tags, seja o primeiro a adicionar uma tag!
|